| This article has been cited by |
| 1 | Capecitabine | |
| Reactions Weekly.2019;1741(1)70 |
| [DOI] |
|
| 2 | Capecitabine-induced activation of actinic keratosis: A common but underrecognized adverse event | |
| Samantha Marley,Shelly Stepenaskie,Naiara S. Barbosa |
| Current Problems in Cancer: Case Reports.2021;3(1)100050 |
| [DOI] |
|
| 3 | Management of Cancer-Associated Myositis | |
| Albert Selva-O’Callaghan,Ernesto Trallero-Araguás,Javier Ros,Albert Gil-Vila,Julia Lostes,Antonia Agustí,Judit Riera-Arnau,Marcelo Alvarado-Cárdenas,Iago Pinal-Fernandez |
| Current Treatment Options in Rheumatology.2022;8(4)91 |
| [DOI] |
|
| 4 | Management of Cancer-Associated Myositis | |
| Kewal K. Jain |
| Current Treatment Options in Rheumatology.2021;8(4)493 |
| [DOI] |
|
| 5 | Dermatomyositis induced by the secretion of Phyllomedusa bicolor or Kambô frog - A case report | |
| Mariana de la Vega,Gilberto Maldonado,Arnoldo Kraus |
| Toxicon.2020;184(4)57 |
| [DOI] |
|
| 6 | Antibody–drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management | |
| SudhirChandra Sarangi,Pranav Sopory,SoumyaSucharita Pattnaik,KH Reeta |
| Indian Journal of Pharmacology.2020;52(5)402 |
| [DOI] |
|
